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Background
Immunotherapy with T cells expressing chimeric antigen
receptors (CARs) specific for a tumor cell-surface mole-
cule is effective for CD19+ B cell malignancies. There is
interest in extending CAR-T cell therapy to epithelial
tumors, which requires identifying molecules that can be
targeted safely. The receptor tyrosine kinase-like orphan
receptor 1 (ROR1) is expressed at the cell-surface in
chronic lymphocytic leukemia, mantle cell lymphoma, and
many epithelial malignancies where it contributes to
tumor survival. ROR1 is also abundantly expressed in
embryogenesis but the cell surface isoform is absent from
vital adult tissues by Western blot. However, ROR1 is
expressed on pre-B cells and adipocytes, and low levels of
transcripts are detected in lung and pancreas, raising con-
cern that targeting ROR1 may cause serious toxicity, as
seen in clinical trials of gene-modified T cells for other
targets that are not completely tumor-restricted in expres-
sion. We developed a CAR (R12) that recognizes a region
of ROR1 conserved in macaques and humans but not
mice. Here, we transduced autologous T cells from
macaca mulatta with the R12-CAR and a control vector,
and studied their safety, migration, and persistence after
adoptive transfer.
Methods
ROR1-expression was examined by quantitative RT-PCR.
Lymphoreplete macaques received T cell infusions consist-
ing of 1-5x108/kg ROR1-CAR and control T cells that
each expressed a unique cell surface marker for in vivo-
tracking. Clinical/organ toxicity, T cell persistence, and
cytokines were monitored. CAR-T cell function was deter-
mined by ablation of ROR1+ B cell precursors and
response to challenge with autologous ROR1-transfected
T cells.
Results
ROR1-expression was comparable in human and macaque
tissues. Macaque ROR1-CAR-T cells were infused without
acute toxicity and persisted in the blood for >3 weeks,
albeit at lower levels than control T cells administered at
the same cell dose. ROR1-CAR-T cells migrated preferen-
tially to bone marrow and lymph nodes and eliminated
endogenous ROR1+ B cells, which coincided with transient
increases in plasma IFN-g and IL-6. ROR1-CAR-T cells
remained functional in vivo as demonstrated by a 7.7-fold
increase in number in response to infusion of ROR1+
T cells.
Conclusion
High doses (5x108/kg) of functional ROR1-CAR-T cells
can be adoptively transferred to macaques without acute
toxicity supporting targeting ROR1 in human cancers with
CAR-T cells. The induction of transgene product-specific
immunity limited long-term persistence of CAR-T cells
and analysis of late toxicity, however our data illustrates
the value of this model for acute safety-studies for candi-
date targets for CAR-T cells.
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